Regenxbio Inc (RGNX) USD0.0001

Sell:$9.15Buy:$9.16$0.05 (0.54%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$9.15
Buy:$9.16
Change:$0.05 (0.54%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$9.15
Buy:$9.16
Change:$0.05 (0.54%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Key people

Curran M. Simpson
President, Chief Executive Officer, Director
Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Olivier Danos
Executive Vice President, Chief Scientific Officer
Patrick J. Christmas
Executive Vice President, Chief Strategy and Legal Officer
Stephen Pakola
Executive Vice President, Chief Medical Officer
Kenneth T. Mills
Chairman of the Board
Daniel Tasse
Lead Independent Director
Allan M. Fox
Director
Jean Bennett
Independent Director
Alexandra Glucksmann
Independent Director
Click to see more

Key facts

  • EPIC
    RGNX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US75901B1070
  • Market cap
    $444.54m
  • Employees
    353
  • Shares in issue
    50.12m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.